v3.26.1
Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)
3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2026
Apr. 30, 2025
Apr. 30, 2026
Apr. 30, 2025
Jul. 31, 2025
Cash flows from operating activities          
Net loss for the period $ (7,237,055) $ (6,224,929) $ (22,812,276) $ (18,392,033)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Amortization     11,453 11,453  
Financial income, net     (143,204)  
Depreciation     74,871 68,517  
Share-based compensation     1,012,749 776,879  
Share of loss on equity investment 64,303 62,738 171,126 176,837  
Change in fair value of warrants (123,242) (175,826) (265,818) (366,024)  
Unrealized gain on investment (137,830) (137,830)  
Changes in working capital:          
Increase (decrease) in amounts receivable and prepaid expenses     (216,031) 466,820  
Decrease in accounts payable     (1,109,266) (3,891,577)  
Increase in accrued expenses and other payables     721,774 1,111,053  
Total cash flow from operating activities     (22,692,452) (20,038,075)  
Cash flows from Investing activities          
Purchase of equipment     (127,049)  
Purchase of short-term investments     (15,781,000)  
Proceeds from short-term investments     7,372,473  
Equity investment in BC Therapeutics     (260,000) (255,000)  
Total cash flow from investing activities     (8,795,576) (255,000)  
Cash flows from financing activities          
Proceeds from exercise of warrants     821,015  
Proceeds from the issuance of shares, net of issuance costs     27,874,441 31,070,224  
Total cash flow from financing activities     27,874,441 31,891,239  
Increase (decrease) in cash and cash equivalents     (3,613,587) 11,598,164  
Cash and cash equivalents at beginning of the period     10,493,808 862,089 $ 862,089
Cash and cash equivalents at end of the period $ 6,880,221 $ 12,460,253 $ 6,880,221 $ 12,460,253 $ 10,493,808